Abstract
ABSTRACT
Standard heparin is widely used for the prevention and treatment of venous thromboembolism; however, it has several limitations including variable dose response, dose-dependent clearance and inhibition of platelet function. To overcome these disadvantages, standard heparin, which is composed of glycosaminoglycans of various molecular weights, has been fractionated into its low-molecular-weight component. Low-molecularweight heparin (LMWH) exhibits less binding to plasma proteins and endothelial cells than standard heparin resulting in a more predictable dose response profile, a dose-independent mechanism of clearance and a longer plasma half-life. LMWH also has a lower binding affinity for platelets and produces less microvascular bleeding. Evidence from randomized clinical trials demonstrates that LMWH is effective in the prevention of deep vein thrombosis (DVT) in high-risk orthopedic patients. There is also considerable evidence of its efficacy and safety in the initial treatment of proximal DVT. Recent studies have demonstrated the feasibility of home treatment with LMWH, which offers the advantage of greater clinical utility compared with current antithrombotic regimens and hence the possibility of cost savings.
- 1 - Hirsh J. Drug therapy. Heparin. N Engl J Med. 1991;324:1565-1574. > Google Scholar
- 2. Hirsh J, Levine M. Low molecular weight heparin. Blood. 1992; 79:1-17. > Google Scholar
- 3. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low-molecular-weight heparin fractions: The influence of the method of preparation. Thromb Res. 1984; 35:613-625. > Google Scholar
- 4. Turpie AGG. Thromboprophylaxis in orthopaedic surgery. Orthopaedics International. 1993; 1:396-402. > Google Scholar
- 5. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologie surgery. N Engl J Med. 1988;318:1162-1173. > Google Scholar
- 6. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery. A meta-analysis. Lancet. 1992;340:152-156. > Google Scholar
- 7. Mohr DN, Silverstein MD, Murtaugh PA, et al. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med. 1993; 153:2221-2228. > Google Scholar
- 8. Clagett GP, Anderson FA Jr, Heit J, Levine M. Prevention of venous thromboembolism. Chest. 1995; 108:312S-334S. > Google Scholar
- 9. Hyers TM. Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995; 108:335S-351S. > Google Scholar
- 10. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A metaanalysis. Arch Intern Med. 1995; 155:601-607. > Google Scholar
- 11. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med. 1996;334:677-681. > Google Scholar
- 12. Koopman MMW, Prandoni P, Piovella F, et al (for the Tasman Study Group). Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med. 1996; 334:682-687. > Google Scholar
